Of the nearly 4 million births each year in the United States, roughly 50,000 are marked by life-threatening complications, and up to 900 result in maternal death during delivery. One major, often life-threatening complication is placenta accreta spectrum (PAS), which poses a threat to both the mother and the baby. Currently, PAS cases are identified by ultrasounds, MRIs, and predictive confounding conditions — but these methods leave between 33% and 50% of PAS cases undetected prior to delivery. A new study by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, embarked on a study to create a targeted test for predicting PAS during pregnancy, thus better preparing patients and practitioners for the delivery day. By studying circulating microparticle (CMP) protein panels in pregnant women, the team identified five unique CMP proteins that can predict PAS as early as the second trimester of pregnancy. Their results are published in Scientific Reports.
“PAS is a significant contributor to maternal morbidity and mortality worldwide,” said corresponding author Hope Yu, MD, a Maternal-Fetal Medicine physician in the Department of Obstetrics and Gynecology at the Brigham. “Before our study, up to half of these cases weren’t able to be detected before delivery. Our study aims to improve that detection rate using a blood test and to eventually improve health outcomes worldwide.”
Placenta accreta, a condition where the placenta attaches excessively into the uterine wall, gets its “spectrum” designation because of varying degrees of placental penetration into the body that can occur. In some cases, the placenta attaches to the uterine muscle; in more severe cases, the placenta attaches through the uterine wall and to other organs, like the bladder. There are two major complications for PAS patients: abnormal placenta delivery after birth and heavy bleeding. Identification of PAS cases prior to delivery can help reduce and prepare for such complications.
To identify PAS early, the Brigham team looked to proteins associated with CMPs. CMPs are tiny, extracellular vesicles that cells use to communicate with one another and have been studied extensively in other disciplines since they provide a glimpse into cell crosstalk. The team set out to study CMPs at the maternal-fetal interface, with the goals of pinpointing a clinically useful PAS biomarker and investigating CMP mechanisms of PAS pathogenesis. The team’s primary goal was to construct a blood panel to identify PAS pregnancies.
The team conducted a nested case-control study with 35 PAS patients and 70 control patients, who all were retroactively diagnosed after delivery. CMP proteins were isolated and identified from patient plasma sampled during the second and third trimesters of pregnancy. In samples collected from patients who were 26 weeks pregnant, five CMP proteins distinguished PAS patients from control patients; at 35 weeks pregnant, four CMP proteins distinguished PAS patients from control patients. Additionally, in the second trimester iron homeostasis and erythropoietin signaling were overrepresented — a trend that, in the third trimester, revealed abnormal immune function.
The study successfully identified five second trimester CMP protein PAS indicators and four third trimester CMP protein PAS indicators, enabling safe predication of PAS well before delivery. The authors note that more research and clinical trials will be needed to further test the applicability of the protein panel. Next steps include widening the patient sample size and creating a standardized commercial test.
“It is so important to identify these cases prior to delivery,” said Yu. “If we can identify a PAS case during pregnancy, the patient can then make a potentially life-saving choice to deliver in a tertiary delivery center with specialized providers. Having an experienced, multidisciplinary team by your side during a PAS birth can make an enormous difference when it comes to mortality and morbidity outcomes.”
“This is another step toward proactive, personalized prenatal care,” added Thomas McElrath, MD, PhD, senior author and also a Maternal-Fetal Medicine physician in the Department of Obstetrics and Gynecology at the Brigham. “Right now, prenatal care too often assumes that every person has the same risks of complications during pregnancy. To be able to personalize and make each patient’s care profile particular to their needs is the ultimate goal.”
Disclosures: P Gurnani, RC Doss, and KP Rosenblatt are employees of NX Prenatal Inc. TF McElrath serves on the Scientific Advisory Board of NX Prenatal in which he holds equity. The remaining authors report no competing interests.
Funding: The study was funded by Sidman Family Foundation (TFM).
Story Source:
Materials provided by Brigham and Women’s Hospital. Note: Content may be edited for style and length.
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
